178 related articles for article (PubMed ID: 1394341)
41. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody.
Chrastina A; Pastoreková S; Pastorek J
Neoplasma; 2003; 50(1):13-21. PubMed ID: 12687273
[TBL] [Abstract][Full Text] [Related]
42. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin.
Koppe MJ; Soede AC; Pels W; Oyen WJ; Goldenberg DM; Bleichrodt RP; Boerman OC
Int J Cancer; 2003 Oct; 106(6):965-72. PubMed ID: 12918078
[TBL] [Abstract][Full Text] [Related]
43. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
44. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
45. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
46. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD
Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345
[TBL] [Abstract][Full Text] [Related]
47. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
48. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
49. Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.
Rosenfeld ME; Rogers BE; Khazaeli MB; Mikheeva G; Raben D; Mayo MS; Curiel DT; Buchsbaum DJ
Clin Cancer Res; 1997 Jul; 3(7):1187-94. PubMed ID: 9815798
[TBL] [Abstract][Full Text] [Related]
50. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts.
Kranenborg MH; Boerman OC; de Weijert MC; Oosterwijk-Wakka JC; Corstens FH; Oosterwijk E
Cancer; 1997 Dec; 80(12 Suppl):2390-7. PubMed ID: 9406688
[TBL] [Abstract][Full Text] [Related]
51. The influence of monoclonal antibody dose on tumor uptake of radiolabeled antibody.
Wahl RL; Liebert M; Wilson BS
Cancer Drug Deliv; 1986; 3(4):243-9. PubMed ID: 3567845
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.
Berger MA; Masters GR; Singleton J; Scully MS; Grimm LG; Soltis DA; Albone EF
Cancer Biother Radiopharm; 2005 Dec; 20(6):589-602. PubMed ID: 16398611
[TBL] [Abstract][Full Text] [Related]
54. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
55. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
56. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
57. Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model.
Roberson PL; Dudek S; Buchsbaum DJ
Cancer; 1997 Dec; 80(12 Suppl):2567-75. PubMed ID: 9406711
[TBL] [Abstract][Full Text] [Related]
58. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.
Baranowska-Kortylewicz J; Abe M; Pietras K; Kortylewicz ZP; Kurizaki T; Nearman J; Paulsson J; Mosley RL; Enke CA; Ostman A
Cancer Res; 2005 Sep; 65(17):7824-31. PubMed ID: 16140951
[TBL] [Abstract][Full Text] [Related]
59. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography.
Muthuswamy MS; Roberson PL; Ten Haken RK; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):165-72. PubMed ID: 8641915
[TBL] [Abstract][Full Text] [Related]
60. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
